Core Viewpoint - The study highlights the urgent need for innovative treatment strategies to prevent the progression from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to Metabolic Dysfunction-Associated Steatotic Hepatitis (MASH), which can lead to irreversible liver damage [2][3]. Group 1: Research Findings - The research published by a team from Shanghai Jiao Tong University indicates that a high-sugar diet leads to the production of endogenous acetaldehyde by gut microbiota, which damages the liver and accelerates the progression from MASLD to MASH without alcohol consumption [2][7]. - Approximately 30.69% of the global population is affected by MASLD, with about 16.02% progressing to MASH, and these numbers are expected to rise with increasing obesity rates [5]. - The study identifies that excessive dietary fructose accelerates the progression from MASLD to MASH through the mediation of endogenous acetaldehyde generated by gut microbiota [7][9]. Group 2: Mechanism and Treatment Strategy - The research team discovered that acetaldehyde produced by gut microbiota enters the liver via the portal vein, upregulating MMP7 expression and activating hepatic stellate cells (HSC), promoting fibrosis in mouse and cell models [7]. - To combat this pathogenic pathway, the team isolated a probiotic strain, Ligilactobacillus salivarius CTMT1, capable of clearing acetaldehyde, and engineered a strain with enhanced acetaldehyde degradation capabilities [7]. - The engineered probiotics effectively reduced liver fibrosis and inflammation in preclinical models, suggesting a promising therapeutic strategy targeting gut microbiota-mediated aldehyde metabolism to prevent MASH [9].

Core Viewpoint - The article discusses the role of the gut microbiome, specifically the bacterium Catenibacterium mitsuokai, in promoting hepatocellular carcinoma (HCC) through mechanisms involving gut barrier disruption and metabolic product secretion [2][3][5]. Group 1: Research Findings - A new carcinogenic gut bacterium, Catenibacterium mitsuokai, has been identified, which promotes the development of HCC by binding to hepatocytes and generating quinolinic acid [3][6]. - Catenibacterium mitsuokai is enriched in the feces and tumors of HCC patients, and it accelerates the carcinogenesis process in both conventional and germ-free mice [5][10]. - The bacterium disrupts the gut barrier and transfers to the liver, where it adheres to HCC cells via the interaction of its surface protein Gtr1/RagA with the γ-catenin receptor on cancer cells [6][10]. Group 2: Mechanistic Insights - The tumor-promoting effect of Catenibacterium mitsuokai is dependent on its secretion of the metabolite quinolinic acid [6][9]. - Quinolinic acid binds to the TIE2 receptor on HCC cells, activating the downstream oncogenic PI3K/AKT pathway, thereby facilitating the progression of liver cancer [6][9].